Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab combination in unresectable pleural mesothelioma
NCT05930665Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in pleural mesothelioma, sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 36 months. Started Nov 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT05930665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930665.